Neurogeneticists have discovered a novel genetic mutation and associated buildup of toxic proteins in the brain -- a type of buildup distinct from amyloid or tau, proteins that have long been the ...

The root causes of most forms of Alzheimer's disease largely remain a mystery. Now, researchers have revealed a new piece of ...

The research, published today in eLife, is described by editors as a fundamental study providing insights into how mutations ... amyloid precursor protein (APP), which—once processed into amyloi ...

In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

The mutation causes the brain to produce versions of the amyloid protein that are prone to clumping into the sticky plaques thought to drive neurodegeneration. Family members with the mutation ...

Icelandic genomics company Arctic Therapeutics has closed ... in a phase IIb/III European trial in cystatin C amyloid angiopathy, an ultra-rare disease found only in Iceland that is caused by the L68Q ...

While the trial is limited to members of families with genetic mutations that all but guarantee they will ... can remove plaques of a key Alzheimer’s protein called amyloid beta from the brain or ...

While the trial is limited to members of families with genetic mutations that all but guarantee ... of a key Alzheimer's protein called amyloid beta from the brain or block them from accumulating ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...